Studie - Amnesia – Pipeline Review, H1 2012

Amnesia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Amnesia - Pipeline Review, H1 2012', provides an overview of the Amnesia therapeutic pipeline. This report provides information on the therapeutic development for Amnesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amnesia. 'Amnesia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Amnesia.
- A review of the Amnesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Amnesia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Amnesia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Amnesia pipeline depth and focus of Amnesia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Amnesia Overview 5

Therapeutics Development 6

An Overview of Pipeline Products for Amnesia 6

Amnesia Therapeutics under Investigation by Universities/Institutes 8

Mid Clinical Stage Products 9

Comparative Analysis 9

Amnesia Therapeutics — Products under Investigation by Universities/Institutes 10

Amnesia — Therapeutics Assessment 11

Assessment by Monotherapy Products 11

Assessment by Route of Administration 12

Assessment by Molecule Type 14

Drug Profiles 16

Rosuvastatin - Drug Profile 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Midazolam Hydrochloride - Drug Profile 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Midazolam - Drug Profile 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Amnesia Therapeutics - Dormant Products 19

Appendix 20

Methodology 20

Coverage 20

Secondary Research 20

Primary Research 20

Expert Panel Validation 20

Contact Us 21

Disclaimer 21





List of Tables

Number of Products Under Development for Amnesia, H1 2012 6

Products under Development for Amnesia — Comparative Analysis, H1 2012 7

Number of Products under Investigation by Universities/Institutes, H1 2012 8

Comparative Analysis by Mid Clinical Stage Development, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Assessment by Monotherapy Products, H1 2012 11

Assessment by Stage and Route of Administration, H1 2012 13

Assessment by Stage and Molecule Type, H1 2012 15

Amnesia Therapeutics — Dormant Products 19





List of Figures

Number of Products under Development for Amnesia, H1 2012 6

Products under Development for Amnesia — Comparative Analysis, H1 2012 7

Products under Investigation by Universities/Institutes, H1 2012 8

Mid Clinical Stage Products, H1 2012 9

Assessment by Monotherapy Products, H1 2012 11

Assessment by Route of Administration, H1 2012 12

Assessment by Stage and Route of Administration, H1 2012 13

Assessment by Molecule Type, H1 2012 14

Assessment by Stage and Molecule Type, H1 2012 15

• Alcohol Addiction – Pipeline Review, H1 2013
• Anesthetic Effect – Pipeline Review, H1 2013
• Anorexia Nervosa Global Clinical Trials Review, H1, 2013
• Chronic Pain – Pipeline Review, H1 2013
• Delirium Global Clinical Trials Review, H1, 2013
• Depression – Pipeline Review, H1 2013
• Dyskinesia Global Clinical Trials Review, H1, 2013
• Dyslexia Global Clinical Trials Review, H1, 2013
• Dystonia Global Clinical Trials Review, H1, 2013
• Friedreich Ataxia – Pipeline Review, H1 2013
• Global Neurostimulation Devices Market 2012-2016
• Ischemic Stroke – Pipeline Review, H1 2013
• Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013
• Memory Impairment – Pipeline Review, H1 2013
• Mild Cognitive Impairment – Pipeline Review, H1 2013
• Partial Seizure – Pipeline Review, H1 2013
• Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2013
• Psychiatric Disorders – Pipeline Review, H1 2013
• Radiculopathy Global Clinical Trials Review, H1, 2013
• Tardive Dyskinesia Global Clinical Trials Review, H1, 2013